South Korea Beefs Up Infrastructure To Lead Asia In Early-Stage Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea is drawing more Phase I and Phase II clinical trials from its former foothold in Phase III and post-approval trials, Korea National Enterprise for Clinical Trials reported
You may also be interested in...
South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub
Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.
Korea FDA To Consider Substantial Reduction To IND Timeframe
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.